このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Capricor Therapeutics 将来の成長

Future 基準チェック /26

Capricor Therapeuticsは、55%と38.3%でそれぞれ年率55%で利益と収益が成長すると予測される一方、EPSはgrowで56.4%年率。

主要情報

55.0%

収益成長率

56.4%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	38.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 Jun 2024

今後の成長に関する最新情報

Recent updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Oct 14

Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

Sep 25

Capricor Therapeutics slumps 9% on $75M stock offering

Jun 21

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

May 16

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Mar 13

Capricor signs intellectual property license for COVID-19 serology test platform

Feb 01

Capricor and Lonza tie up in DMD development

Jan 12

業績と収益の成長予測

NasdaqCM:CAPR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	76	-12	-11	N/A	5
12/31/2025	49	-29	-44	N/A	5
12/31/2024	22	-38	-9	N/A	5
3/31/2024	27	-24	-33	-31	N/A
12/31/2023	25	-22	-28	-26	N/A
9/30/2023	14	-29	-23	-21	N/A
6/30/2023	9	-29	-21	-18	N/A
3/31/2023	6	-29	-18	-15	N/A
12/31/2022	3	-29	2	5	N/A
9/30/2022	2	-27	4	6	N/A
6/30/2022	N/A	-25	7	9	N/A
3/31/2022	0	-23	9	11	N/A
12/31/2021	0	-20	-18	-17	N/A
9/30/2021	0	-18	-16	-15	N/A
6/30/2021	0	-18	-15	-15	N/A
3/31/2021	0	-17	-13	-12	N/A
12/31/2020	0	-14	-11	-10	N/A
9/30/2020	0	-11	-8	-8	N/A
6/30/2020	1	-9	-7	-7	N/A
3/31/2020	1	-7	-6	-6	N/A
12/31/2019	1	-8	-7	-7	N/A
9/30/2019	1	-9	-9	-9	N/A
6/30/2019	2	-12	-10	-10	N/A
3/31/2019	2	-14	-12	-12	N/A
12/31/2018	2	-15	-14	-14	N/A
9/30/2018	1	0	-13	-13	N/A
6/30/2018	2	2	-13	-13	N/A
3/31/2018	2	2	-13	-13	N/A
12/31/2017	3	2	N/A	-14	N/A
9/30/2017	3	-14	N/A	-15	N/A
6/30/2017	4	-17	N/A	-14	N/A
3/31/2017	4	-18	N/A	-15	N/A
12/31/2016	4	-19	N/A	-14	N/A
9/30/2016	4	-18	N/A	-15	N/A
6/30/2016	5	-15	N/A	-16	N/A
3/31/2016	5	-14	N/A	-13	N/A
12/31/2015	6	-13	N/A	-11	N/A
9/30/2015	6	-11	N/A	-9	N/A
6/30/2015	6	-10	N/A	-8	N/A
3/31/2015	6	-8	N/A	-12	N/A
12/31/2014	5	-6	N/A	1	N/A
9/30/2014	3	-9	N/A	3	N/A
6/30/2014	2	-9	N/A	1	N/A
3/31/2014	1	-9	N/A	6	N/A
12/31/2013	1	-9	N/A	-6	N/A
9/30/2013	1	-5	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CAPR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CAPR今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CAPR今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CAPRの収益 ( 38.3% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CAPRの収益 ( 38.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CAPRの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Capricor Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 24%, EPS downgraded

Forecast breakeven date pushed back to 2026

Consensus revenue estimates increase by 41%

Consensus revenue estimates fall by 51%

Consensus revenue estimates increase by 86%

Forecast breakeven date moved forward to 2024

Recent updates

Capricor Therapeutics, Inc. Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. Announces for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Profitability

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 24%, EPS downgraded

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Capricor Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc., Annual General Meeting, May 14, 2024

Consensus revenue estimates increase by 41%

Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

New major risk - Financial position

Capricor Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Consensus revenue estimates fall by 51%

New minor risk - Market cap size

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. Appoints Michael Kelliher to Its Board of Directors

New minor risk - Share price stability

Consensus revenue estimates increase by 86%

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insufficient new directors

Capricor Therapeutics Announces the Appointment of Philip J. Gotwals to Its Board of Directors

Capricor Therapeutics, Inc Announces Board Changes

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Chief Business Officer exercised options and sold US$51k worth of stock

Independent Director notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

Forecast to breakeven in 2025

Now 26% undervalued after recent price drop

Consensus revenue estimates increase by 146%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Forecast to breakeven in 2024

Now 20% undervalued after recent price drop

Capricor Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Capricor Therapeutics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Capricor Therapeutics, Inc. Announces First Patient Dose in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Independent Director recently sold US$79k worth of stock

Capricor Therapeutics, Inc. Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with Cap-1002 in Hope-2 Open Label Extension Study

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

Forecast to breakeven in 2023

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Capricor Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$15.00

Insufficient new directors

Capricor Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory Inspire Trial in Severe Hospitalized Covid-19 Patients

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022